查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
普伐他汀市场 2022-2028
市场调查报告书
商品编码
1215663

普伐他汀市场 2022-2028

Pravastatin Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3个工作天内

价格

在预测期内，普伐他汀的全球市场预计将以 5.4% 的复合年增长率增长。 不断增加的药物研究活动正在为市场创造发展机会。 例如，2021 年 7 月，一项从 2020 年 1 月到 2020 年 9 月的全美国医院范围的研究将表明，他汀类药物可降低既往患有高血压和心脏病的 COVID-19 患者的死亡风险。我是。 该研究包括 104 家美国医院的大约 10,500 名患者。 所有人都因 COVID-19 重病住院。 美国心臟协会对数据的分析得出结论，他汀类药物的使用同样可以将 COVID-19 感染导致严重后果的风险降低 25%。 普伐他汀可降低血液中的低密度脂蛋白（坏）胆固醇和甘油三酯，并增加高密度脂蛋白（好）胆固醇。 它仅作为仿製药销售，没有品牌药。 它也仅以平板电脑形式出售。 该报告进一步打算分析在预测期内直接或间接影响普伐他汀市场增长的所有主要和次要因素。

全球普伐他汀市场根据剂量类型和最终用户进行细分。 根据剂量类型，市场分为 10 毫克片剂、20 毫克片剂、40 毫克片剂和 80 毫克片剂。 基于最终用户，市场分为儿科和成人。 这些部分可以根据要求的研究要求进一步定制。

从地域上看，全球普伐他汀市场分为北美、欧洲、亚太地区和世界其他地区。 我们还可以应要求提供特定地区或国家层面的市场分析。 欧洲在普伐他汀的全球市场中占有很大份额。 推动欧洲市场增长的因素包括心血管疾病患病率上升。 根据 2017 年欧洲心血管疾病统计，欧洲每年有 390 万人死于心血管疾病，欧盟伙伴国家每年有 180 万人死于心血管疾病。 这分别占欧洲和欧盟登记死亡人数的 45% 和 37%。 因此，日益加重的心血管疾病负担将增加该地区对普伐他汀医药产品的需求。

内容

第 1 章报告概述

  • 当前行业分析和增长前景
  • COVID-19 对全球普伐他汀市场的影响
  • 全球普伐他汀市场的复苏情景
  • 研究方法和工具
  • 市场细分
    • 按细分
    • 按地区

第 2 章市场概述和洞察

  • 调查范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 推荐
    • 总结

第三章竞争格局

  • 主要公司分析
    • 百时美施贵宝公司
    • 诺华国际公司
    • Glenmark Pharmaceuticals Ltd.
    • 雷迪博士实验室有限公司
  • 关键策略分析
  • COVID-19 对主要参与者的影响

第四章市场细分

  • 全球普伐他汀市场：按剂量类型分类
    • 10 毫克片剂
    • 20 毫克片剂
    • 40 毫克片剂
    • 80 毫克片剂
  • 全球普伐他汀市场：按最终用户分类
    • 儿科
    • 成人

第五章区域分析

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 意大利
    • 西班牙
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 其他亚太地区
  • 世界其他地方

第六章公司简介

  • Accord Healthcare, Ltd.
  • Apotex, Inc.
  • Aurobindo Pharma Ltd.
  • Cipla, Inc.
  • Daiichi Sankyo Co
  • Jiangxi Boyaseehot Pharmaceutical Co., Ltd.
  • Lupin Ltd.
  • Mylan N.V.
  • North China Pharmaceutical Group
  • Shanghai Shyndec Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Upsher-Smith Laboratories, LLC
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Zydus Pharmaceuticals, Inc.
Product Code: OMR2026719

Title:Global Pravastatin Market Size, Share, and Trends Analysis Report, by Dosage Type (10 mg Tablet, 20 mg Tablet, 40 mg Tablet, and 80 mg Tablet) and by End User (Children and Adults), Forecast Period (2022-2028).

The global pravastatin market is anticipated to grow at a CAGR of 5.4% during the forecast period. The rising pharmaceutical research activities are generating development opportunities for the market. For instance, in July 2021, a study was conducted across the US hospitals between January and September 2020 to show that the Statins reduce the risk of mortality in COVID-19 patients with a history of high blood pressure or heart disease. The study was conducted on around 10,500 patients across 104 US hospitals. All of them had been admitted with a serious COVID-19 disease. After analyzing the data by American Heart Association, it was concluded that statin use was similarly linked to a 25% lower risk for developing a severe outcome as a result of COVID-19 infection. Pravastatin reduces LDL (bad) cholesterol and triglycerides in the blood and increases HDL (good) cholesterol. It is only available as a generic drug and it doesn't have a brand name version. It comes only in the form of a tablet. This report will further analyze all the primary as well as secondary factors that are directly or indirectly influencing the growth of the pravastatin market during the forecast period.

The global pravastatin market is segmented based on dosage type and end-users. Based on the dosage type, the market is segmented into 10 mg tablets, 20 mg tablets, 40 mg tablets, and 80 mg tablets. Based on the end-users, the market is sub-segmented into children and adults. These segments can further be customized as per the requested research requirements.

Geographically, the global pravastatin market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The market can also be analyzed for a particular region or country level as per the requirement. Europe holds a considerable share in the global pravastatin market. The factors driving the European market growth include the rising prevalence of cardiovascular disorders. According to the European Cardiovascular Disease Statistics 2017, there were 3.9 million fatalities reported due to cardiovascular diseases every year in Europe, while 1.8 million deaths were reported in the EU partner nations every year. This represents 45% and 37% of the total fatalities registered across the Europe and EU respectively. Thus, the rising burden of cardiovascular disease will increase the demand for pravastatin drugs in this region.

The major companies serving the global pravastatin market include Bristol-Myers Squibb, Novartis International AG, Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Cipla Inc., Lupin Ltd., Aurobindo Pharma Ltd., and Teva Pharmaceutical Industries Ltd., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market.

Research Methodology

The market study of the global pravastatin market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Pravastatin Market Research and Analysis by Dosage Type.
  • Global Pravastatin Market Research and Analysis by End User.

The Report Covers:

  • Comprehensive research methodology of the global pravastatin market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global pravastatin market.
  • Insights about market determinants that are stimulating the global pravastatin market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Pravastatin Market
  • Recovery Scenario of Global Pravastatin Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Bristol-Myers Squibb, Co.
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. Novartis International AG
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Glenmark Pharmaceuticals Ltd.
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Dr. Reddy's Laboratories, Ltd.
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

  • 4.1. Global Pravastatin Market by Dosage Type
    • 4.1.1. 10 mg Tablet
    • 4.1.2. 20 mg Tablet
    • 4.1.3. 40 mg Tablet
    • 4.1.4. 80 mg Tablet
  • 4.2. Global Pravastatin Market by End User
    • 4.2.1. Children
    • 4.2.2. Adults

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Accord Healthcare, Ltd.
  • 6.2. Apotex, Inc.
  • 6.3. Aurobindo Pharma Ltd.
  • 6.4. Cipla, Inc.
  • 6.5. Daiichi Sankyo Co
  • 6.6. Jiangxi Boyaseehot Pharmaceutical Co., Ltd.
  • 6.7. Lupin Ltd.
  • 6.8. Mylan N.V.
  • 6.9. North China Pharmaceutical Group
  • 6.10. Shanghai Shyndec Pharmaceutical Co. Ltd.
  • 6.11. Teva Pharmaceutical Industries Ltd.
  • 6.12. Upsher-Smith Laboratories, LLC
  • 6.13. Zhejiang Hisun Pharmaceutical Co., Ltd.
  • 6.14. Zydus Pharmaceuticals, Inc.

LIST OF TABLES

  • 1. GLOBAL PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL 10 MG PRAVASTATIN TABLETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL 20 MG PRAVASTATIN TABLETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL 40 MG PRAVASTATIN TABLETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL 80 MG PRAVASTATIN TABLETS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)
  • 7. GLOBAL PRAVASTATIN FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL PRAVASTATIN FOR ADULTS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. NORTH AMERICAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 11. NORTH AMERICAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)
  • 13. EUROPEAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 14. EUROPEAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 15. EUROPEAN PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)
  • 16. ASIA-PACIFIC PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 17. ASIA-PACIFIC PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)
  • 19. REST OF THE WORLD PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 20. REST OF THE WORLD PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY END USER, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL PRAVASTATIN MARKET, 2021-2028 ($ MILLION)
  • 2. GLOBAL PRAVASTATIN MARKET SHARE BY DOSAGE TYPE, 2021 VS 2028 (%)
  • 3. GLOBAL 10 MG PRAVASTATIN TABLETS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 4. GLOBAL 20 MG PRAVASTATIN TABLETS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. GLOBAL 40 MG PRAVASTATIN TABLETS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 6. GLOBAL 80 MG PRAVASTATIN TABLETS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 7. GLOBAL PRAVASTATIN MARKET SHARE BY END USER, 2021 VS 2028 (%)
  • 8. GLOBAL PRAVASTATIN FOR CHILDREN MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 9. GLOBAL PRAVASTATIN OF ADULTS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 10. GLOBAL PRAVASTATIN MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 11. US PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 12. CANADA PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 13. UK PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 14. FRANCE PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. GERMANY PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. ITALY PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. SPAIN PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. REST OF EUROPE PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. INDIA PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. CHINA PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. JAPAN PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. REST OF ASIA-PACIFIC PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. REST OF THE WORLD PRAVASTATIN MARKET SIZE, 2021-2028 ($ MILLION)